阿奇霉素联合辛伐他汀对慢性阻塞性肺疾病合并肺动脉高压患者肺功能的影响

目的:探讨阿奇霉素联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床疗效及对患者肺功能的影响。方法:选取2013年6月-2016年3月我院收治的慢性阻塞性肺疾病合并肺动脉高压患者107例,根据治疗方法不同分为对照组(49例)与实验组(58例)。对照组患者采用阿奇霉素治疗,实验组患者在对照组基础上给予辛伐他汀治疗。观察并比较两组患者的临床疗效、不良反应以及肺功能指标的变化情况。结果:实验组患者治疗有效率(87.93%)高于对照组(73.47%),差异具有统计学意义(P0.05)。与治疗前比较,两组患者治疗后1 s用力呼吸容积(FEV1)、用力肺活量(FVC)及FEV1/FVC水平均升高,差异具有统计学意义(P0.05);与对照组比较,实验组患者治疗后1 s用力呼吸容积(FEV1)、用力肺活量(FVC)及FEV1/FVC水平较高,差异具有统计学意义(P0.05)。治疗后,两组患者血清总胆固醇(TC)及三酰甘油(TG)水平均降低,差异具有统计学意义(P0.05);与对照组比较,实验组患者治疗后血清总胆固醇(TC)及三酰甘油(TG)水平较低,差异具有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:阿奇霉素联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床效果显著,不仅能够改善患者肺功能,降低血脂相关指标水平,并且安全性较高,值得临床推广应用。

Efficacy of Azithromycin Combined with Simvastatin in Treatment of COPDComplicated with Pulmonary Hypertension

Objective:To investigate the clinical efficacy of azithromycin combined with simvastatin in the treatment of chronicobstructive pulmonary disease (COPD) and pulmonary hypertension and the effects on pulmonary function of patients.Methods:107 caseswith chronic obstructive pulmonary disease and pulmonary hypertension who were treated in our hospital from June 2013 to March2016 were selected and according to the different treatment methods, the patients were divided into the control group (49 cases) and theexperimental group (58 cases). The patients in the control group were treated with azithromycin, and the patients in the experimentalgroup were treated with simvastatin on the basis of the control group. Then the clinical efficacy, the adverse reactions and the changes ofpulmonary function indexes in the two groups were observed and compared before and after the treatment.Results:The clinical effectiverate in the experimental group was 87.93%, which was higher than 73.47% in the control group, and the difference was statistically significant(P<0.05). Compared with before treatment, the FEV1, FVC and FEV1/FVC in the two groups increased after the treatment, andthe differences were statistically significant (P<0.05); Compared with the control group, the FEV1, FVC and FEV1/FVC in the experimentgroup were higher, and the differences were statistically significant (P<0.05); Compared with before treatment, the levels of TC andTG of patients in the two groups decreased, and the differences were statistically significant (P<0.05); Compared with the control group,the levels of TC and TG of patients in the experiment group were lower, and the differences were statistically significant (P<0.05). Therewas no significant difference about the incidence of adverse reactions between the two groups (P>0.05).Conclusion:Azithromycin combinedwith simvastatin on the treatment of COPD and pulmonary hypertension is effective, which can improve the pulmonary functions,reduce the lipid indexes and it is safe and worthy of clinical application.